Get started
Author

Kengo Umehara

Observed names: K. Umehara, KENGO UMEHARA, 梅原健吾
ORCID: 0000-0001-8722-7395
Observed ORCID: 0000-0001-8722-7395
OpenAlex ID: A5042932125
Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer
2022 · Shinya Takada, Hidetaka Murooka, et al. · Asian Pacific Journal of Cancer Prevention · 29
PDF
Correlation between antibiotic use and antibiotic resistance: A multicenter study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system in Hokkaido, Japan
2022 · Keisuke Kagami, Nobuhisa Ishiguro, et al. · American Journal of Infection Control · 17
PDF
Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer
2021 · Kengo Umehara, Kaori Yama, et al. · Cancer Control · 10
PDF
Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients
2023 · Shinya Takada, Hideki Maeda, et al. · Biological and Pharmaceutical Bulletin · 8
PDF
Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation
2023 · Shinya Takada, Hideki Maeda, et al. · Asian Pacific Journal of Cancer Prevention · 6
PDF
Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study
2020 · Kengo Umehara, Kaori Yama, et al. · Renal Replacement Therapy · 4
PDF
Prediction of Severe Anemia and Neutropenia Induced by Abemaciclib in Patients With Breast Cancer
2025 · SHINYA TAKADA, KENGO UMEHARA, et al. · Anticancer Research · 3
Pharmacist Intervention in Outpatients With Prostate Cancer Prevents Apalutamide-induced Skin Adverse Events
2024 · KENGO UMEHARA, YOSHITAKA SAITO, et al. · In Vivo · 3
PDF
Usefulness of Hospital and Community Pharmacists Collaborating to Manage Capecitabine-induced Severe Hand-foot Syndrome in Patients with Breast Cancer
2024 · Shinya Takada, Kengo Umehara, et al. · Asian Pacific Journal of Cancer Prevention · 3
PDF
Renin‑angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab
2022 · Takeshi Chiba, Haruki Ujiie, et al. · Biomedical Reports · 3
PDF
Real-world implementation of a standardized administration protocol for zolbetuximab-associated nausea and vomiting: a retrospective supportive-care cohort study
2026 · Tamotsu Sagawa, Kengo Umehara, et al. · Supportive Care in Cancer · 2
Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib
2026 · SHINYA TAKADA, KENGO UMEHARA, et al. · In Vivo · 2
PDF
Risk Factors for Eribulin-induced Severe Neutropenia in Patients With Recurrent Breast Cancer
2023 · SHINYA TAKADA, YOSHIHIRO HOSOKAWA, et al. · In Vivo · 2
PDF
Association between Area under the Curve Estimated from Carboplatin Dose and Incidence of Severe Thrombocytopenia in Patients with Non-Hodgkin’s Lymphoma on DeVIC Therapy
2023 · Kengo Umehara, Shinya Takada, et al. · Asian Pacific Journal of Cancer Prevention · 2
PDF
Serum Albumin Affects the Time-to-treatment Failure of Alectinib: A Multicenter Retrospective Study
2023 · KENGO UMEHARA, KAORI YAMA, et al. · In Vivo · 2
PDF
Impact of Abemaciclib-Induced Serum Creatinine Elevation on Dose Adjustment of Concomitant Medications
2025 · Kengo Umehara, Yoshitaka Saito, et al. · Oncology · 1
Mineralocorticoid receptor antagonists for VEGF-pathway inhibitor-associated hypertension and proteinuria: biological rationale, clinical evidence, and a hypothesis-generating framework
2026 · Tamotsu Sagawa, Kengo Umehara, et al. · Medical Oncology
Antiemetic Efficacy of Aprepitant in Cisplatin–Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study
2026 · KENGO UMEHARA, YOSHITAKA SAITO, et al. · Anticancer Research
Preventive Effects of SGLT2 Inhibitors on Cisplatin-Induced Nephrotoxicity in Patients with Solid Tumors and Diabetes: A Multicenter, Retrospective Cohort Study
2026 · Masaya Kanda, Toshinobu Hayashi, et al. · Research Square
PDF
Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment
2026 · Shinya Takada, Kaori Takahashi, et al. · Scientific Reports
PDF
92P Concomitant use of proton pump inhibitors and palbociclib or abemaciclib in patients with endocrine-sensitive advanced breast cancer: A multicenter retrospective study
2025 · H. Kawazoe, R. Uozumi, et al. · Annals of Oncology
Analysis of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Left Ventricular Dysfunction
2023 · Yasuhisa Hashino, Kengo Umehara, et al. · Journal of Biophysical Chemistry
PDF
Comparative study on safety after primary and secondary treatment in EGFR positive NSCLC administered Osimertinib
2019 · Kengo Umehara, Keisuke Gto, et al. · Annals of Oncology
[Comparative Study of the Antiemetic Palonosetron for Lung Cancer Patients Treated with a Divided Dose of Cisplatin].
2016 · Kengo Umehara, Azusa Wakamoto, et al. · PubMed
[Study on the Antiemetic Effects of Aprepitant in Patients with Lung Cancer Receiving Chemotherapy with Carboplatin].
2015 · Tae Hatsuyama, Kengo Umehara, et al. · PubMed
Works count: 27
Citation count: 97
H-index: 5
I10-index: 3
Year
Topic
Type